Indication
Claudication
9 clinical trials
9 products
2 drugs
Clinical trial
An Open-Label, Randomized, Two-Treatment, Two-Sequence, Four-Period, Fully Replicated Crossover Bioequivalence Study of Once Daily PMR Compared to Twice Daily Cilostazol IR Tablets in Healthy VolunteersStatus: Completed, Estimated PCD: 2023-12-22
Product
PMR TabletProduct
CilostazolClinical trial
A Prospective, Randomized, Placebo-controlled, Double-blinded, Multi-center, Phase IV, Exploratory Clinical Trial to Demonstrate the Effect of Improving the Walking Distance by GNX80 in Patients With Intermittent ClaudicationStatus: Recruiting, Estimated PCD: 2024-03-01
Product
GNX80Product
PlaceboProduct
SarpogrelateClinical trial
A Double-blinded, Randomized, Placebo-controlled Study of GFH312 in Patients With Peripheral Artery Disease (PAD) and Intermittent Claudication (IC)Status: Withdrawn, Estimated PCD: 2023-12-31
Clinical trial
A Randomized, Multicenter, Open-label, Parallel, Phase 4 Clinical Trial to Evaluate the Efficacy and Safety of Sarpogrelate SR in Patients Having Intermittent Claudication Among Chronic Artery Occlusive DiseaseStatus: Completed, Estimated PCD: 2023-03-09
Product
GFH312Clinical trial
An Open-Label, Randomized, Two-Treatment, Two-Sequence, Four-Period, Fully Replicated Crossover Bioequivalence Study of Once Daily PMR Compared to Twice Daily Cilostazol IR Tablets in Healthy VolunteersStatus: Terminated, Estimated PCD: 2022-05-04
Product
PMRClinical trial
An Open-Label, Randomized, Two-Treatment, Two-Sequence, Four-Period, Fully Replicated Crossover Bioequivalence Study of Once Daily PMR Compared to Twice Daily Cilostazol IR Tablets in Healthy VolunteersStatus: Completed, Estimated PCD: 2022-08-23
Clinical trial
Metformin BenefIts Lower Extremities With Intermittent Claudication (MOBILE_IC)Status: Recruiting, Estimated PCD: 2026-02-28
Drug
MetforminDrug
placeboClinical trial
DVC1-0101 for Intermittent Claudication Secondary to Peripheral Artery Disease: a Randomized Phase IIb TrialStatus: Active (not recruiting), Estimated PCD: 2021-12-01
Product
DVC1-0101Clinical trial
A Prospective, Randomized, Open-label, Multicenter Study Comparing Rivaroxaban 2.5 mg Twice Daily Associated With Aspirin 100 mg Once Daily Versus Aspirin 100 mg Once Daily in Patients With Peripheral Arterial Disease and Limiting Intermittent Claudication. (The COMPASS CLAUDICATION Trial).Status: Completed, Estimated PCD: 2023-02-01
Product
Rivaroxaban